2′-,5′-oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-α2b plus ribavirin therapy in patients with chronic hepatitis C

被引:10
作者
Kim, K. -I.
Kim, S. -R.
Sasase, N.
Taniguchi, M.
Harada, S.
Kinoshita, K.
Kim, S. -H.
Akimoto, Y.
Shikata, M.
Kimura, N.
Izawa, S.
Ohtani, A.
Nakao, K.
Motojima, M.
Kinoshita, M.
Hirai, M.
Ohzu, M.
Hirooka, T.
Nabeshima, S.
Ishii, F.
Tanaka, K.
Hotta, H.
机构
[1] Kobe Asahi Hosp, Dept Gastroenterol, Nagata Ku, Kobe, Hyogo 6530801, Japan
[2] Kobe Asahi Hosp, Dept Pharm, Kobe, Hyogo, Japan
[3] Kobe Asahi Hosp, Med Informat Ctr, Kobe, Hyogo, Japan
[4] Kobe Pharmaceut Univ, Fac Pharmaceut Sci, Kobe, Hyogo 658, Japan
[5] Osaka Univ Pharmaceut Sci, Osaka 580, Japan
[6] Kobe Univ, Sch Med, Dept Microbiol, Kobe, Hyogo, Japan
关键词
2; 5 '-oligoadenylate synthetase; chronic hepatitis C; PEG-interferon-alpha; 2b; ribavirin;
D O I
10.1111/j.1365-2710.2006.00761.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Although all the mechanisms of elimination of hepatitis C virus (HCV) by Interferon (IFN) have not been fully elucidated, the 2'-5'-oligoadenylate (2-5A) system is one of the mechanisms of the antiviral effect of IFN. Consequently, the measurement of 2'-5'-oligoadenylate synthetase (2-5AS) activity could be useful for the evaluation of IFN treatment. This retrospective study was aimed at assessing whether 2-5AS activity functions as a clinical marker of virological response to PEG-interferon-alpha 2b (PEG-IFN) plus ribavirin therapy of chronic hepatitis C. Methods: The 32 patients included in this study had high viral loads of serum HCV-RNA of genotype 1b with chronic hepatitis C. All the patients received a regimen of PEG-IFN plus ribavirin for 48 weeks, and were then divided into two groups: one group (effective group) with undetectable serum HCV-RNA levels at 24 weeks (n = 22) of therapy, the other group (ineffective group) with persistent presence of HCV-RNA in serum at 24 weeks (n = 10). The 2-5AS activity in serum was measured 2, 8 and 12 weeks before initial administration. Results: The 2-5AS response ratio (measured value/measured value of baseline 2-5AS) at 2, 8 and 12 weeks after the administration in the effective group was significantly higher than that in the ineffective group. Conclusions: These results suggest that the ratio of 2-5AS is closely related to the antiviral effect, and that the measurement of 2-5AS response ratio may be a useful clinical parameter of virological response to PEG-IFN plus ribavirin therapy of chronic hepatitis C.
引用
收藏
页码:441 / 446
页数:6
相关论文
共 25 条
[1]   Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum [J].
Ampurdanes, S ;
Olmedo, E ;
Maluenda, MD ;
Forns, X ;
LopezLabrador, FX ;
Costa, J ;
SanchezTapias, JM ;
deAnta, MTJ ;
Rodes, J .
JOURNAL OF HEPATOLOGY, 1996, 25 (06) :827-832
[2]   Hepatitis C virus core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon α-2b plus ribavirin [J].
Buti, M ;
Mendez, C ;
Schaper, M ;
Sauleda, S ;
Valdes, A ;
Rodriguez-Frias, F ;
Jardi, R ;
Esteban, R .
JOURNAL OF HEPATOLOGY, 2004, 40 (03) :527-532
[3]   Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype [J].
Chayama, K ;
Suzuki, F ;
Tsubota, A ;
Akuta, N ;
Someya, T ;
Kobayashi, M ;
Arase, Y ;
Saitoh, S ;
Suzuki, Y ;
Ikeda, K ;
Kumada, H .
JOURNAL OF VIROLOGICAL METHODS, 2001, 95 (1-2) :33-45
[4]   A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C [J].
Glue, P ;
Rouzier-Panis, R ;
Raffanel, C ;
Sabo, R ;
Gupta, SK ;
Salfi, M ;
Jacobs, S ;
Clement, RP .
HEPATOLOGY, 2000, 32 (03) :647-653
[5]   Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection [J].
Hu, KQ ;
Vierling, JM ;
Redeker, AG .
JOURNAL OF VIRAL HEPATITIS, 2001, 8 (01) :1-18
[6]   A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load [J].
Izumi, N ;
Asahina, Y ;
Kurosaki, M ;
Uchihara, M ;
Nishimura, Y ;
Inoue, K ;
Ueda, K ;
Tsuchiya, K ;
Hamano, K ;
Itakura, J ;
Miyake, S .
INTERVIROLOGY, 2004, 47 (02) :102-107
[7]  
Karino Y, 1994, Hokkaido Igaku Zasshi, V69, P1354
[8]   Early hepatitis C virus RNA responses predict interferon treatment outcomes in chronic hepatitis C [J].
Lee, WM ;
Reddy, KR ;
Tong, MJ ;
Black, M ;
van Leeuwen, DJ ;
Hollinger, FB ;
Mullen, KD ;
Pimstone, N ;
Albert, D ;
Gardner, S .
HEPATOLOGY, 1998, 28 (05) :1411-1415
[9]   Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].
Manns, MP ;
McHutchison, JG ;
Gordon, SC ;
Rustgi, VK ;
Shiffman, M ;
Reindollar, R ;
Goodman, ZD ;
Koury, K ;
Ling, MH ;
Albrecht, JK .
LANCET, 2001, 358 (9286) :958-965
[10]   TGF-β1 mRNA expression in liver biopsy specimens and TGF-β1 serum levels in patients with chronic hepatitis C before and after antiviral therapy [J].
Marek, B ;
Kajdaniuk, D ;
Mazurek, U ;
Janczewska-Kazek, E ;
Kos-Kudla, B ;
Strzalka, B ;
Fila, A ;
Niedziolka, D ;
Beniowski, M ;
Ostrowska, Z ;
Borgiel-Marek, H ;
Kajdaniuk, J ;
Sieminska, L ;
Nowak, M ;
Wilczok, T ;
Pakula, D ;
Filipczyk, P .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2005, 30 (03) :271-277